Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

June 25, 2019

Tesaro’s niraparib secures FDA priority review for late stage ovarian cancer

Tesaro, a GlaxoSmithKline (GSK) company, has secured priority review designation for its polymerase (PARP) inhibitor ZEJULA (niraparib) from the US Food and Drug Administration (FDA) for the treatment of late stage ovarian cancer.

Tesaro’s niraparib secures FDA priority review for late stage ovarian cancer